AstraZeneca - Improving patient outcomes in early-stage and advanced EGFR-mutant NSCLC: Emerging strategies (ID 42)

Time
12:00 - 13:30

Improving patient outcomes in early-stage and advanced EGFR-mutant NSCLC: Emerging strategies (ID 1205)

Live audience Q&A (ID 1209)